Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. Cotte L et al., J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):346-54 Posted on August 17th, 2013 - Pr François Raffi Back to Home page
Back to Home page